MIDN and breast carcinoma: Based on the Human Protein Atlas (HPA) database, we found that MIDN, NR4A1, PSMC1, and EGR1 were all positively expressed in liver cancer, pancreatic cancer, urothelial cancer, breast cancer, and melanoma (Figure 5G).